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Abstract
Focal segmental glomerulosclerosis (FSGS) is the most common primary glomerular disease in nephrotic patients in the United States, 
frequently leading to end stage renal disease (ESRD). The cellular variant is a rare form of FSGS commonly associated with poor outcome. 
We report a case of cellular variant FSGS with progressive kidney dysfunction successfully treated with plasma exchange (PE). A 49-year-old 
Caucasian female presented with two days of ankle edema and hypertension. Laboratory findings showed serum creatinine (SCr) 1.6 mg/dL, 
urine albumin/creatinine ratio (uACR) 2.8 g/g, haematuria 3+ and no immunological abnormalities. Kidney biopsy revealed a cellular FSGS 
variant with segmental endocapillary proliferation on light microscopic, negative immunofluorescence and widespread foot process effacement 
by electronic microscopic. Prednisolone 1 mg/Kg was started. Four days later the SCr worsened (3.6 mg/dL) and the patient became severely 
nephrotic with uACR of6.8g/g, quickly attaining a maximum of 24.6 g/g in a short time and albumin of 2.15g/dL. Pulsed methyl prednisolone 
was started. Despite a 10 course of steroids, no clinical improvement was observed. Considering the rapidly worsening renal function and 
severe nephrotic syndrome, PE was begun in association with mycophenolate mofetil and tacrolimus. Kidney function recovered after one week. 
Complete remission was achieved at 3rd week and remains in complete remission at 27 months follow-up. Prolonged remission is a challenge in 
primary FSGS. PE associated with combined immunosuppression was effective in the present case. The short and long-term effects of plasma 
exchange in primary FSGS should be evaluated in prospective studies.
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Introduction 
Focal segmental glomerulosclerosis (FSGS) is the most common 
diagnosis in adult nephrotic patients in the United States (35% off all 
cases), mainly in African American descents (50%) and is also the most 
common primary glomerular disease leading to end-stage renal disease 
(ESRD) in both Caucasian and African American descents. However, in a 
Spanish based population, membranous nephropathy (24%) is the leading 
cause of nephrotic syndrome in patients between 15 and 65 years, while 
FSGS is the 4th most common cause (12%) [1]. FSGS is characterized 
by podocyte injury and foot process effacement leading to the typical 
histologic findings of obliteration of glomerular capillaries by extracellular 
matrix accumulation, representing the focal and segmental sclerosis [2,3]. 
FSGS is a histological pattern that can represent different etiologies [4]. 
Based on the etiology, FSGS could be classified as idiopathic (primary), 
genetic, adaptive (secondary), virus-associated and drug-induced [2]. 
Primary or idiopathic FSGS is a ‘primary’ podocytopathy presumably 
caused by a putative circulating permeability factor and characterized by 
nephrotic syndrome and FSGS lesion at light microscopy with widespread 
foot process effacement in electron microscopy (EM) [4,2]. The successful 
treatment of recurrent FSGS after transplant with plasma exchange (PE) 
is in favor of a circulating permeability factor as a cause for this lesion 
pattern [5]. 
The histologic framework provided by the NY-Columbia classification 
describes five distinct FSGS variants based on light microscopy patterns 
[3], encompassing FSGS not otherwise specified (NOS), perihilar, cellular, 
tip lesion and collapsing variants. Cellular variant is a rare form of FSGS 
(3% of all FSGS) frequently presenting with severe nephrotic syndrome 
and associated with acute kidney injury and hypertension [6-8], commonly 
with poor outcomes [5]. We herein present a patient with cellular variant 
FSGS with severe nephrotic syndrome and rapid worsening of kidney 
functionsuccessfully treated with PE and immunosuppressive regimen.
Case Report 
A 49-year-old Caucasian female with no relevant past medical 
history presented to her general practitioner with two days complain of 
ankle edema. The urine dipstick analysis showed 3+ protein. One week 
before, she had complained of abdominal pain and diarrhea for two 
days that spontaneously remitted. She had previous laboratory findings 
documenting normal kidney function and no family history of kidney 
disease. She also denied taking any drug recently. On observation at 
Nephrology Department showed blood pressure of 154/92 mmHg and 1+ 
pitting ankle edema. Laboratory findings showed serum creatinine (SCr) 
1.6 mg/dL, urine albumin/creatinine ratio (uACR) 2.8 g/g, microscopic 
hematuria 3+, sediment with no acanthocytes, serum albumin 2.5 g/dL 
and total cholesterol 231 mg/dL. The chest X-ray showed bilateral pleural 
effusion and kidney ultrasound was unremarkable. Further investigation 
showed no complement abnormalities, negative autoantibodies and 
negative viral serology. A kidney biopsy was performed showing cellular 
FSGS variant, with exuberant segmental endocapillary proliferation with 
increased cell infiltration and slight mesangial expansion (Figure 1). There 
were no features of acute tubular injury or chronic interstitial nephritis 
lesions. Immunofluorescence was negative. Electron microscopy showed 
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exuberant diffuse effacement of the pedicels, with no evidence of electron 
dense deposits or endothelial tubuloreticular inclusions (Figure 1). 
Treatment with steroids was started (prednisolone 1 mg/Kg/day) and 
she was discharged on loop diuretics and angiotensin converting enzyme 
inhibitor. Four days later, she was admitted with worsened hypertension 
(162/92 mmHg), anasarca and worsened kidney function (SCr 3.24 
mg/d). On admission, she showed uACR of 6.8 g/g, attaining a maximum 
of 24.6 g/g in a short time and serum albumin was 2.15 mg/dL. Pulse 
methylprednisolone was done (0.5 g qd for 3 days). Considering the rapidly 
worsening kidney function with severe nephrotic proteinuria despite 10 
days of steroid treatment, we changed the therapeutic approach. PE was 
initiated (6 daily and 1 on alternative day) associated to the previous dose 
of prednisolone (1 mg/Kg/day), mycophenolate mofetil (MMF) (1 g bid) 
and tacrolimus (0.5 mg bid, aiming for very low serum levels of 2 ng/mL). 
One week after this was started, she showed marked improvement with 
edema regression, normal blood pressure and recovering kidney function 
(eGFR 72 ml/min/1.72m²). Complete remission was achieved at 1 month 
follow-up (3rd week of treatment). High dose steroid was continued for 
another month and then slowly tapered off. MMF was also reduced at 
7 month follow-up. At 15 month follow-up the patient remained in 
complete remission (Figure 2) and MMF was further reduced aiming for 
withdrawal. The patient relapsed two months later (uACR 3.6 g/g with 
normal kidney function). The MMF dose was then increased to 0.5 g bid 
and complete remission was achieved after 2 weeks. At 27 month follow-
up, the patient remains in complete remission with no adverse events or 
side effects to report (Figure 2).
 
Figure 1: Renal biopsy light and electronic microscopy
Light microscopy: A– Exuberant cell proliferation with discrete mesangial expansion and increased cell infiltration by mononuclear; B – Segmental 
endocapillary hypercellularity, discrete mesangial expansion and apparent glomeruli-capsular synechiae (arrow). Electron microscopy: C– Area of 
segmental sclerosis (arrow); diffuse foot process effacemen; D – Capillary loop with exuberant hyperplasia of endothelial cells and diffuse foot process 
effacement (arrow); E – Capillary loop filled with cells (exuberant endocapillary proliferation), at the expense of leukocytes (inflammatory cell (IC)), 
erythrocytes (E), hyperplastic endothelial cells (EC) and platelets and diffuse foot process effacement.
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FSGS represents a histologic pattern of podocyte damage with 
different causes and frequently undefined pathogenesis. FSGS is one of 
the most serious glomerular diseases, with frequent progression to ESRD 
and with a high rate of recurrence in kidney allografts [4]. The clinical 
classification based on etiology distinguishes five forms: primary or 
idiopathic FSGS, the etiology of which is largely unknown; secondary or 
adaptive, which commonly refers to an adaptive response to glomerular 
hypertrophy/hyperfiltration or represent a nonspecific pattern of scarring 
due to a previous injury; genetic; drug-induced; virus-associated [2]. 
The mechanisms responsible for the podocytopathy are still unknown. A 
presumed circulating permeability factor has been proposed to play a role 
in the pathogenesis of primary FSGS [9]. Recurrence in renal allografts 
provides the best evidence for the existence of this circulating factor, but 
its nature remains unclear. The efficacy of PE in reducing proteinuria 
following recurrence reinforces this theory [5]. Additionally, there are 
diverse clinical and experimental studies that support the existence of 
circulating factors [4]. Despite extensive research, these circulating factors 
have not been identified or characterized. Five distinct FSGS variants 
were classified based on light microscopic patterns in NY-Columbia FSGS 
classification [3]: FSGS not otherwise specified (NOS), perihilar, cellular, 
tip lesion and collapsing variants. Several studies have documented 
significant differences in clinical findings and outcomes between these 
morphological patterns [6-7]. The cellular variant of FSGS is defined 
by the presence of at least one glomerulus with segmental expansion of 
the glomerular tuft with endocapillary hypercellularity, often with foam 
cells, with or without hyperplasia of overlying visceral epithelial cells and 
exclusion of FSGS tip and collapsing variants [3]. It usually presents with 
heavy proteinuria, severe nephrotic syndrome, acute kidney injury and 
hypertension in more than half of the cases [6-8]. It is less frequent then 
the other FSGS variants (3% of all FSGS [9]) and shows intermediate rates 
of remission (44.5%), acute kidney injury (57.1%) and progression to 
ESRD (27.8%), when compared to the collapsing and tip lesion variants 
[6]. Other authors have described 67% of cases with no remission [8].
However, the low number of cellular variant cases reported, make it 
difficult to understand its prognosis and response to treatment. Here 
we present a case of severe nephrotic syndrome and acute kidney injury 
secondary to cellular FSGS variant who was successfully treated with 
combined PE and immunosuppression, an approach similar to that used 
in allograft recurrent FSGS after kidney transplant and also described 
in therapy resistance FSGS in native kidney. This case shows a clinical 
presentation very close to what has been described in the literature. 
However, the patient kept getting worse after one week of steroid 
treatment. The notable worsening of kidney function and a significant 
increase in proteinuria led to a change to the treatment approach. 
First-line treatment for primary FSGS is corticosteroids. Nevertheless, 
steroid resistance is common [4,10]. The identified predictors of kidney 
outcomes in FSGS are the amount of proteinuria, kidney function at 
presentation and tubule and interstitial damage. However, patients 
who achieve complete or partial remission have better renal outcomes 
than those who do not. Achieving complete or partial remission is 
the stronger predictor of kidney survival [11]. Therefore alternative 
immunosuppressive therapy is needed when steroids fail to achieve 
this goal. Calcineurin inhibitors, either cyclosporine or tacrolimus, can 
be used for steroid-resistant FSGS or with frequent relapses [10,11], 
particularly because these show an anti-proteinuric profile. MMF in 
association with low-dose prednisolone also seemed to be as effective 
as high-dose prednisolone in a prospective trial [12]. In our case, the 
rapid worsening of kidney function and the reported low remission rate 
in cellular FSGS variant led us to change the treatment for a combined 
immunosuppression. In order to rapidly control the disease progression 
while waiting for immunosuppression action, we believe that PE was 
crucial for the removal of a putative permeability factor and preventing 
further damage.
The presumed existence of a “glomerular permeability factor” explains 
the rapid relapse after transplantation and the efficacy of plasma exchange 
in this setting [4,3]. Plasma exchange has been used for treatment of 
transplant recurrence FSGS with suitable results [5]. In a systematic 
review and meta-analysis of PE treatment in post-transplant FSGS, 
overall complete or partial remission was 71% [13]. Rare cases have been 
published using this approach as rescue therapy in native kidney disease 
with encouraging results if used with concomitant immunosupression 
theraphy [13-15]. 
 
Figure 2: Renal function and proteinuria evolution during follow-up
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In a study including 11 patients with biopsy-proven FSGS, unresponsive 
to steroids and cytotoxic therapy, PE was performed 17 times during a 
median 22 weeks in addiction to oral prednisolone and intravenous 
cyclophosphamide. At 27 months follow-up 6 patients had complete 
remission (and stabilized kidney function) and 2 parcial remission [14]. 
On the other hand, less good results with PE were observed in 
others studies. In a small study including 5 patients with native kidney 
FSGS resistant to standard immunosuppressive therapy (steroids, 
cyclophosphamide and cyclosporine) and using immune adsorption, 
proteinuria reduction by more than 50% was observed in only 2 patients. 
In another study PE was performed in 8 patients with steroid-resistent 
idiopathic FSGS in native kidney, after a mean 12 months from initial 
presentation. These patients had received prednisone at a dose of 40 to 60 
mg/day for an average of 4.4 months and in 5 this was followed by three 1g 
doses of IV methylprednisolone. Six PE treatments were then performed 
over 2 weeks and most patients continued to receive a tapering dose of 
prednisone. Proteinuria decreased in two of eight patients, although 
only transiently in one of the two. Both had stable renal function in the 
last follow-up [15]. The lack of greater response observed in these 2 last 
studies could be related to less intensive immunosuppression therapy. 
In our case, early PE with combined immunosuppression showed 
effective to achieve complete remission. It also showed good results in 
long term follow-up with normal kidney function and no side effects of 
treatment. Since cellular variant FSGS is associated with just one third 
of response to steroids and rapid kidney loss, PE can be an option for 
preventing further damage in severe cases and long-term morbidity 
improving clinical outcome. The independent effect of PE in the treatment 
of primary FSGS in native kidney disease has yet be confirmed in 
prospective studies as well as its long-term effect.
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